Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - bevacizumab - concentrate for solution for infusion - 100mg - bevacizumab

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - bevacizumab - concentrate for solution for infusion - 400 mg - bevacizumab

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - bisoprolol fumarate - film-coated tablet - 5mg - bisoprolol

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - filgrastim - solution for injection in pre-filled syringe - 30 miu - filgrastim

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - desloratadine - film-coated tablet - 5mg - desloratadine

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - trastuzumab - solution for infusion - 440 mg - trastuzumab

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - zolmitriptan - film-coated tablet - 2.5mg - zolmitriptan

Kenya - English - Pharmacy and Poisons Board

cadila healthcare limited zydus tower, satellite cross roads, ahmedabad 380 - zolmitriptan - film-coated tablet - 5mg per tablet - zolmitriptan

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

zydus lifesciences limited, india - teneligliptin - tablet, film-coated - 20

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 30 mg - paroxetine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets, usp in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology —clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets, usp in hospitalized depressed patients have not been adequately studied. the efficacy